[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cancer Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Type (Chimeric Antibodies, Humanized Antibodies), By Application (Blood Cancer, Breast Cancer, Lung Cancer), By End-user, By Region, And Segment Forecasts, 2022 - 2030

July 2022 | 150 pages | ID: C38D4EFAE3D5EN
Grand View Research, Inc.

US$ 5,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 4 Business Days

Cancer Monoclonal Antibodies Market Growth & Trends

The global cancer monoclonal antibodies market size is expected to reach USD 159.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.2% from 2022 to 2030. The increasing prevalence of cancer, and product approvals along with a robust pipeline are the key factors augmenting the market growth. Furthermore, an increase in funding for R&D in this sector is expected to impact industrial growth. Moreover, the booming biosimilar market will further offer lucrative opportunities during the forecast period.

Non-small Cell Lung Cancer (NSCLC) is a common type of lung cancer. For patients with metastatic NSCLC, the prognosis is mostly poor, as only about 8% will live beyond 5 years after the diagnosis. Moreover, at present, there are no HER2-directed therapies approved precisely for treating HER2-mutant non-small cell lung cancer, which occurs in almost 2-4% of patients with non-squamous NSCLC. However, progress has been made over the last two years, mainly in the first-line setting, leaving a substantial unmet medical need. For instance, in April 2022, Daiichi Sankyo and AstraZeneca received acceptance of supplemental Biologics License Application (sBLA) of Enhertu in the U.S. for treating adult patients with unresectable NSCLC.

The development of monoclonal antibodies has been great both in clinical and technical research applications over the past three years. Given their advantages of safety, specificity, and efficacy, there is now prevalent acceptance of mAbs as advanced therapeutic agents. Cancer is the most dominating and important area of medicinal application, accounting for almost 50% of all monoclonal antibodies-related R&D programs.

In addition, in June 2021, the European Commission approved Bristol Myers Squibb’s combination therapy of Yervoy and OPDIVO to treat patients for malignant pleural mesothelioma. In June 2022, Regeneron Pharmaceuticals, Inc. announced its plan to purchase Sanofi's stake in the Sanofi and Regeneron partnership on Libtayo, providing the company with exclusive global development, manufacturing, and commercialization rights to the medicine. Furthermore, in May 2020, Gilead Sciences, Inc. and Arcus Biosciences, Inc. entered into a 10-year partnership to co-commercialize and co-develop recent and future therapeutic candidates in Arcus’s pipeline. Arcus has 10 current clinical studies of molecules in its range with three monoclonal antibodies.

As COVID-19 reached a tipping point in the U.S. and Europe during the last two weeks of March 2020, its far-reaching consequences were observed across industries and businesses, with hospitals postponing or canceling treatment procedures for cancer and halting clinical trials. This has hampered the market growth to an extent. However, as treatment procedures resumed, manufacturers observed a steady improvement in business in the second half of 2021.

Cancer Monoclonal Antibodies Market Report Highlights
  • By type, the humanized segment held a larger share of the market in 2021 owing to factors such as, low cost, availability, and quick production time for mouse monoclonal antibodies. However, the human segment is expected to hold the highest CAGR during the forecast period due to an increase in the number of product approvals and product launches
  • The blood cancer application segment held a significant revenue share in 2021 owing to an increase in the prevalence of hematological disorders along with a robust pipeline. In addition, the lung cancer segment is poised to expand at the highest CAGR during the forecast period
  • In 2021, the hospital segment was the leading end-user segment due to an upsurge in the number of patient hospitalizations. In addition, the availability of innovative drug therapies in the facility drives the patient preference
  • North America dominated the global market in 2021, due to the strategic activities of key market players, increasing cancer cases, and supportive government efforts in this region
  • In Asia Pacific, the market is expected to grow considerably in the future due to the increasing number of international and national collaborations among entities, especially those in developed and developing countries
CHAPTER 1 RESEARCH METHODOLOGY

1.1 Information Procurement
1.2 Data Analysis

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market Snapshot

CHAPTER 3 CANCER MONOCLONAL ANTIBODIES MARKET VARIABLES, TRENDS & SCOPE

3.1 Market Lineage Outlook
  3.1.1 Parent market outlook
  3.1.2 Ancillary market outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Market Segmentation & Scope
3.4 Cancer Monoclonal Antibodies Market Analysis Market Dynamics
3.5 Market Driver Analysis
  3.5.1 Growing prevalance of cancer
  3.5.2 Increasing investement in research and development
  3.5.3 Rising preference for personalized medicines
3.6 Market Restraint Analysis
  3.6.1 High cost of monoclonal antiobdy therpaeutics
3.7 Key Opportunities
  3.7.1 Booming Biosimilar market
3.8 Cancer Monoclonal Antibodies Market - PESTLE analysis
3.9 Industry Analysis - Porter’s
3.10 Major Deals & Strategic Alliances Analysis
  3.10.1 Joint ventures
  3.10.2 Mergers & acquisitions
  3.10.3 Licensing & partnership
  3.10.4 Technology collaborations
  3.10.5 Strategic divestments
3.11 COVID-19 Impact Analysis

CHAPTER 4 CANCER MONOCLONAL ANTIBODIES MARKET: SEGMENT ANALYSIS, BY TYPE, 2018 - 2030 (USD BILLION)

4.1 Cancer Monoclonal Antibodies Market: Type Movement Analysis
4.2 Humanized
  4.2.1 Humanized Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
4.3 Human
  4.3.1 Human Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
4.4 Chimeric
  4.4.1 Chimeric Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
4.5 Murine
  4.5.1 Murine Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

CHAPTER 5 CANCER MONOCLONAL ANTIBODIES MARKET: SEGMENT ANALYSIS, BY APPLICATION, 2018 - 2030 (USD BILLION)

5.1 Cancer Monoclonal Antibodies Market: Application Movement Analysis
5.2 Blood Cancer
  5.2.1 Blood Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
5.3 Breast Cancer
  5.3.1 Breast Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
5.4 Lung Cancer
  5.4.1 Lung Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
5.5 Melanoma
  5.5.1 Melanoma Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
5.6 Colorectal Cancer
  5.6.1 Colorectal Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
5.7 Liver Cancer
  5.7.1 Liver Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
5.8 Others
  5.8.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

CHAPTER 6 CANCER MONOCLONAL ANTIBODIES MARKET: SEGMENT ANALYSIS, BY END-USER, 2018 - 2030 (USD BILLION)

6.1 Cancer Monoclonal Antibodies Market: End-User Movement Analysis
6.2 Hospitals
  6.2.1 Hospitals Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
6.3 Research Institutes
  6.3.1 Research Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
6.4 Others
  6.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

CHAPTER 7 CANCER MONOCLONAL ANTIBODIES MARKET: SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD BILLION)

7.1 Cancer Monoclonal Antibodies Market: Regional Movement Analysis
7.2 North America
  7.2.1 North America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.2.2 U.S.
    7.2.2.1 U.S. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.2.3 Canada
    7.2.3.1 Canada cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
7.3 Europe
  7.3.1 Europe cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.3.2 U.K.
    7.3.2.1 U.K. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.3.3 Germany
    7.3.3.1 Germany cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.3.4 France
    7.3.4.1 France cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
7.4 Asia Pacific
  7.4.1 Asia Pacific cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.4.2 Japan
    7.4.2.1 Japan cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.4.3 China
    7.4.3.1 China cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.4.4 India
    7.4.4.1 India cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
7.5 Latin America
  7.5.1 Latin America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.5.2 Brazil
    7.5.2.1 Brazil cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.5.3 Mexico
    7.5.3.1 Mexico cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
7.6 Middle East and Africa (MEA)
  7.6.1 MEA cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.6.2 South Africa
    7.6.2.1 South Africa cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  7.6.3 Saudi Arabia
    7.6.3.1 Saudi Arabia cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)

CHAPTER 8 COMPETITIVE LANDSCAPE

8.1 Vendor Landscape
  8.1.1 Global Cancer Monoclonal Antibody Market: Key Company Market Share Analysis, 2021
8.2 Company Profiles
  8.2.1 F. HOFFMANN-LA ROCHE LTD
    8.2.1.1 Company overview
    8.2.1.2 Financial performance
    8.2.1.3 Product benchmarking
    8.2.1.4 Pipeline analysis
    8.2.1.5 Strategic initiatives
  8.2.2 BRISTOL MYERS SQUIBB CO.
    8.2.2.1 Company overview
    8.2.2.2 Financial performance
    8.2.2.3 Product benchmarking
    8.2.2.4 Pipeline analysis
    8.2.2.5 Strategic initiatives
  8.2.3 MERCK & CO.
    8.2.3.1 Company overview
    8.2.3.2 Financial performance
    8.2.3.3 Product benchmarking
    8.2.3.4 Pipeline analysis
    8.2.3.5 Strategic initiatives
  8.2.4 GLAXOSMITHKLINE PLC
    8.2.4.1 Company overview
    8.2.4.2 Financial performance
    8.2.4.3 Product benchmarking
    8.2.4.4 Pipeline analysis
    8.2.4.5 Strategic initiatives
  8.2.5 JOHNSON & JOHNSON
    8.2.5.1 Company overview
    8.2.5.2 Financial performance
    8.2.5.3 Product benchmarking
    8.2.5.4 Pipeline analysis
    8.2.5.5 Strategic initiatives
  8.2.6 AMGEN, INC.
    8.2.6.1 Company overview
    8.2.6.2 Financial performance
    8.2.6.3 Product benchmarking
    8.2.6.4 Pipeline analysis
    8.2.6.5 Strategic initiatives
  8.2.7 NOVARTIS AG
    8.2.7.1 Company overview
    8.2.7.2 Financial performance
    8.2.7.3 Product benchmarking
    8.2.7.4 Pipeline analysis
    8.2.7.5 Strategic initiatives
  8.2.8 ASTRAZENECA PLC
    8.2.8.1 Company overview
    8.2.8.2 Financial performance
    8.2.8.3 Product benchmarking
    8.2.8.4 Pipeline analysis
    8.2.8.5 Strategic initiatives
  8.2.9 ELI LILLY AND COMPANY
    8.2.9.1 Company overview
    8.2.9.2 Financial performance
    8.2.9.3 Product benchmarking
    8.2.9.4 Pipeline analysis
    8.2.9.5 Strategic initiatives
  8.2.10 ABBVIE
    8.2.10.1 Company overview
    8.2.10.2 Financial performance
    8.2.10.3 Product benchmarking
    8.2.10.4 Pipeline analysis
    8.2.10.5 Strategic initiatives
LIST OF TABLES

TABLE 1 Cancer monoclonal antibodies market - Industry snapshot & key buying criteria
TABLE 2 Cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 3 Cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 4 Cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 5 Cancer monoclonal antibodies market, by region, 2018 - 2030 (USD Billion)
TABLE 6 North America cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 7 North America cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 8 North America cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 9 U.S. cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 10 U.S. cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 11 U.S. cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 12 Canada cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 13 Canada cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 14 Canada cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 15 Europe cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 16 Europe cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 17 Europe cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 18 U.K. cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 19 U.K. cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 20 U.K. cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 21 Germany cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 22 Germany cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 23 Germany cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 24 France cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 25 France cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 26 France cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 27 Asia Pacific cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 28 Asia Pacific cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 29 Asia Pacific cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 30 Japan cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 31 Japan cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 32 Japan cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 33 China cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 34 China cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 35 China cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 36 India cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 37 India cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 38 India cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 39 Latin America cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 40 Latin America cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 41 Latin America cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 42 Brazil cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 43 Brazil cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 44 Brazil cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 45 Mexico cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 46 Mexico cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 47 Mexico cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 48 MEA cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 49 MEA cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 50 MEA cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 51 South Africa cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 52 South Africa cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 53 South Africa cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
TABLE 54 Saudi Arabia cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
TABLE 55 South Abrabia cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
TABLE 56 South Abrabia cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
LIST OF FIGURES

FIG. 1 Market Research Process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain Based Sizing & Forecasting
FIG. 6 QFD Modelling For Market Share Assessment
FIG. 7 Market summary 2022 (USD Billion)
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Cancer monoclonal antibodies market analysis, 2018 - 2030 (USD Billion)
FIG. 11 Cancer monoclonal antibodies market dynamics
FIG. 12 Market driver relevance analysis (Current & future impact)
FIG. 13 Global pharmaceutical industry, 2014 - 2022 (USD Billion)
FIG. 14 Market restraint relevance analysis (Current & future impact)
FIG. 15 Key Opportunities
FIG. 16 Cancer monoclonal antibodies market PESTEL analysis
FIG. 17 Porter’s Five Forces Analysis
FIG. 18 Cancer monoclonal antibodies market, type outlook key takeaways (USD Billion)
FIG. 19 Cancer monoclonal antibodies market: Type movement analysis (USD Billion)
FIG. 20 Humanized market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 21 Human market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 20 Chimeric market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 21 Murine market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 22 Cancer monoclonal antibodies market, application outlook key takeaways (USD Billion)
FIG. 23 Cancer M monoclonal antibodies market: Therapeutic application movement analysis (USD Billion)
FIG. 24 Blood cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 25 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 26 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 27 Melanoma market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 28 Colorectal cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 29 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 30 Other applications market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 31 Cancer monoclonal antibodies market, end-user outlook key takeaways (USD Billion)
FIG. 32 Cancer monoclonal antibodies market: End-user movement analysis (USD Billion)
FIG. 33 Hospitals market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 34 Research Institutes market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 35 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
FIG. 36 Regional market place: Key takeaways (USD Billion)
FIG. 37 Cancer monoclonal antibodies market: Regional movement analysis (USD Billion)
FIG. 38 North America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 39 U.S. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 40 Canada cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 41 Europe cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 42 U.K. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 43 Germany cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 44 France cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 45 Asia Pacific cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 46 Japan cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 47 China cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 48 India cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 49 Latin America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 50 Brazil cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 51 Mexico cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 52 MEA cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 53 South Africa cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
FIG. 54 Saudi Arabia cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)


More Publications